Health Care • Medical Specialities
$361.39 ▼ -6.77
(-1.84%)
MKT CAP: $29.86B • VOL: 773.8K
52W L $245 52W H $371
LH // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $13.95B | $13.01B | $12.16B |
| YoY Revenue Growth % | +7.2% | +7.0% | — |
| Gross Profit | $4.01B | $3.62B | — |
| Gross Margin % | 28.8% | 27.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $1.38B | $1.09B | $725.6M |
| Operating Margin % | 9.9% | 8.4% | 6.0% |
| Net Income (GAAP) | $877.0M | $746.0M | $418.0M |
| EBITDA (Normalized) | $1.73B | $1.48B | $1.16B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.64B | $1.59B | $1.33B |
| Capital Expenditures (CapEx) | $434.5M | $489.9M | $547.3M |
| Free Cash Flow (FCF) | $1.21B | $1.10B | $780.4M |
| FCF Margin % | 8.6% | 8.4% | 6.4% |
| Return on Invested Capital (ROIC %) | 8.3% | 7.2% | 5.8% |
| Cash & Short-Term Equivalents | $532.3M | $1.52B | — |
| Total Debt (Short + Long Term) | $5.08B | $5.33B | $3.84B |
| Total Stockholders' Equity | $8.62B | $8.05B | $7.88B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LH.